Transcutaneous auricular vagus nerve stimulation for pediatric epilepsy: study protocol for a randomized controlled trial by unknown
TRIALS
He et al. Trials  (2015) 16:371 
DOI 10.1186/s13063-015-0906-8STUDY PROTOCOL Open AccessTranscutaneous auricular vagus nerve
stimulation for pediatric epilepsy: study
protocol for a randomized controlled trial
Wei He1,2, Xiao-Yu Wang1, Li Zhou3, Zhi-Mei Li3, Xiang-Hong Jing1, Zhong-Li Lv4, Yu-Feng Zhao5, Hong Shi1,
Ling Hu1, Yang-Shuai Su1 and Bing Zhu1,2*Abstract
Background: Recently, clinical observations reported the potential benefit of vagus nerve stimulation (VNS) for
pediatric epilepsy. Transcutaneous auricular vagus nerve stimulation (ta-VNS) is a newer non-invasive VNS, making it
more accessible for treating pediatric epilepsy, yet there is limited clinical evidence for its effectiveness.
Methods/Design: A three-center, randomized, parallel, controlled trial will be carried out to evaluate whether ta-VNS
improves pediatric epilepsy. Pediatric patients aged 2 to 14 years with epilepsy will be recruited and randomly
assigned to transcutaneous auricular vagus nerve stimulation (ta-VNS) group, transcutaneous auricular non-vagus nerve
stimulation (tan-VNS) group, and control group with a 1:1: sqrt(2) allocation, as per a computer generated
randomization schedule stratified by study center using permuted blocks of random sizes. We will use Zelen’s design,
in which randomization occurs before informed consent. Patients in the stimulation groups will receive tan-VNS or
ta-VNS three times a day for 6 months. Patients in the control group will not be provided with any stimulation during
the 6 months. The guardians of the patients are required to keep a detailed diary to record the data. Outcome
assessment including seizure frequency, electroencephalogram (EEG), heart rate variability (HRV) analysis, quality of life
(QOL) and adverse events will be made at baseline and 2, 4 and 6 months after ta-VNS initiation. The seizure frequency
and adverse events will be followed up at 1 year and 1.5 years after ta-VNS initiation.
Discussion: Results of this trial will help clarify whether ta-VNS treatment is beneficial for pediatric patients, and will
make clear whether the anticonvulsive effect of ta-VNS is correlated with the improvement of sympathovagal
imbalance.
Trial registration: Clinical Trials Identifier: NCT02004340. Registration date: 13 November 2013.
Keywords: Transcutaneous auricular vagus nerve stimulation, Pediatric epilepsy, Randomized controlled trial, HRVBackground
Vagus nerve stimulation (VNS) has been approved by
US Food and Drug Administration (FDA) as a comple-
mentary treatment for partial refractory epilepsy in pa-
tients aged no less than 12 years, since 1997 [1].
Recently, clinical observations indicated the potential
benefit of VNS for pediatric epilepsy. In a retrospective
review of patients undergoing VNS insertion, it was* Correspondence: zhubing@mail.cintcm.ac.cn
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article, unless otherwise stated.suggested that VNS is a safe and effective adjuvant ther-
apy for children under 12 years old, with over half
reporting significant benefit [2]. Clinical results reported
by the Pediatric VNS Study Group showed a median re-
duction in seizure frequency of 42 % after 18 months of
intermittent stimulation of the left vagal nerve [3].
Recently, newer non-invasive VNS has improved the
safety and tolerability of VNS, making it more accessible
and facilitating further investigations across a wider
range of uses [4]. Transcutaneous auricular vagus nerve
stimulation (ta-VNS) at the innervation area of the aur-
icular branch of the vagus nerve (ABVN) has been uti-
lized in the treatment of epilepsy. In a pilot study ofdistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Fig. 1 Trial flow chart
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patients were seizure-free; 19/47 patients had reduced
seizure frequency [5]. It has also been reported that ta-
VNS can effectively reduce the frequency of seizures and
improve the patient’s quality of life in adult epilepsy pa-
tients [6]. In our pilot trial of ta-VNS for pediatric epi-
lepsy, mean reduction in seizure frequency relative to
baseline was 54.13 % at the end of 24 weeks’ treatment
[7]. Yet no randomized controlled trial (RCT) has been
performed on the safety and efficacy of ta-VNS for pa-
tients with pediatric epilepsy.
Autonomic imbalance has been found to be accom-
panied with epilepsy. An increased sympathetic activity
and reduced parasympathetic activity were observed in
patients with epilepsy [8, 9]. In children with refractory
epilepsy, parasympathetic activity is lower in comparison
with healthy controls [10]. A systematic review con-
firmed a sympathovagal imbalance in epilepsy, as shown
by lower high-frequency (HF) power spectrum, standard
deviation of normal-to-normal interval (SDNN) and root
mean square of successive differences (RMSSD) values
when compared to controls [11].
In the present study, we use transcutaneous auricular
non-vagus nerve stimulation (tan-VNS) as a sham com-
parator, waiting list group as a control. We aim to inves-
tigate the safety and efficacy of ta-VNS in treating
pediatric patients with epilepsy in a multicenter RCT,
and determine whether the anticonvulsive effect of ta-




A multicenter randomized, parallel, controlled trial is
currently being performed. Pediatric patients will be in-
cluded from three centers, including Beijing Tiantan
Hospital and Beijing Children Hospital affiliated to Capital
Medical University, and Acupuncture Hospital affiliated
to the Institute of Acupuncture and Moxibustion, China
Academy of Chinese Medical Sciences. The protocol
has been approved by the Clinical Trial Ethics Commit-
tee of the Institute of Acupuncture and Moxibustion,
China Academy of Chinese Medical Sciences (number:
2012030101) and registered on ClinicalTrials.gov proto-
col registration system (Clinical Trials Identifier:
NCT02004340). Informed consent will be sought from
all the guardians of the participants.
At the beginning of the enrollment, participants in the
control group will be given a diary book to record the
data, including the frequency of seizures and adverse
events. Participants in the stimulation groups will be
given a ta-VNS instrument and a diary book to record
the frequency of seizures, usage of instruments and side-
effects or adverse events. Patients or their guardians willbe required to keep a detailed diary. This trial will in-
clude a 6-month treatment period and a 1.5-year follow-
up period. Outcome assessment of ta-VNS will be made
at baseline and 2, 4 and 6 months, 1 year and 1.5 years
after ta-VNS initiation (Fig. 1).Inclusion criteria
Participants will be included if they meet all of the fol-
lowing conditions: 1) diagnosis of epilepsy, and aged be-
tween 2 and 14 years old; 2) the number and dose of the
medication has been kept constant no less than 2
months before intervention; 3) the number of epileptic
seizures is no less than eight in 2 months; 4) the patients
or their guardians can count the frequency of the sei-
zures and finish the study; and 5) the guardians can
understand the mechanism of the ta-VNS treatment,
voluntarily agree with the study protocol and sign writ-
ten informed consents.Exclusion criteria
Participants will be excluded if they meet any of the fol-
lowing conditions: 1) the patient is receiving VNS ther-
apy; 2) the patient is accompanied with progressive
central nervous disease; 3) the patient has severe heart,
liver or blood disease; or 4) previous participation in this
study.
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Participants will be randomly assigned to either one of the
two stimulations or the control group with a 1:1: sqrt(2)
allocation, as per a computer generated randomization
schedule stratified by the study center using permuted
blocks of random sizes. The block sizes will not be dis-
closed, to ensure concealment. We will use Zelen’s design,
in which randomization occurs before informed consent.
Those patients in the control group (n = 42) receiving
standard care will not be consented for participation in
this study. They will be informed in an observational study
with questionnaires to provide the same measurements,
except for treatment, as that in the treatment groups for
free, and thus blinded. Other participants who accept the
intervention will provide further informed consents, in
which they will be informed to have the possibility of re-
ceiving either one of the two stimulations according to
computerized randomization schedule. The two stimula-
tion groups will include the tan-VNS group (n = 30) and
the ta-VNS group (n = 30). Participants in the control
group and stimulation groups are thus blinded.
The randomization sequence will be generated using
SPSS v.17.0 software (IBM, Armonk, NY, USA) and
distributed in a sealed envelope to the doctor. The re-
searchers will not be permitted to change it after the pa-
tients are randomized. Employees outside the research
team will feed original data into the computer in separ-
ate datasheets so that the researchers can analyze data
without having access to information about the alloca-
tion. The evaluation of the curative effect and the statis-
tical analysis will be evaluated by a third party in the
clinical evaluation center of the China Academy of
Chinese Medical Sciences who will not know the
grouping and patients. In this clinical trial process, the
patients, statisticians and the assessor for statistical
data and outcomes will be blind to treatment allocation.
Allocation concealment will not be exposed until the
final data analysis report is completed.
Interventions
For patients in the ta-VNS group, transcutaneous stimu-
lation will be performed at the bilateral auricular concha
with two pairs of stimulation electrode clips via the ear
vagus nerve stimulator (TENS-200, Suzhou, Jiangsu,
China) [7]. The stimulation electrodes are made of con-
ductive rubber, with a diameter of 5 mm. The anode
electrode is placed on the concha cavity and the cathode
electrode is placed on the cymba concha. For patients in
the tan-VNS group, transcutaneous stimulation will be
performed at the marginal area of the auricle, which is
not innervated by the ABVN. The parameters of the
stimulation are as follows: frequency of 20 Hz; intensity
of 1.0 mA; duration of 30 min; three times a day; and for
a total of 6 months. Professional technicians will trainthe patients or their guardians about the use of the stim-
ulators; patients then take the stimulators home and ini-
tiate the stimulators as needed.
For the control group, no transcutaneous stimulation
is provided during the 6 months.
Outcome measures
Primary outcomes
Seizure frequency: the baseline seizure frequency and the
seizure frequency after 2 months, 4 months and 6 months
of enrollment will be counted according to the patient’s
seizure diary. Seizure outcomes will be expressed with a
modified Engel scale [12].
Secondary outcomes
Video electroencephalogram (EEG): video EEG of each
patient will be recorded for 2 hours before ta-VNS initi-
ation and at the end of ta-VNS, respectively.
Heart rate variability (HRV): HRV of each patient will
also be recorded before ta-VNS initiation and at the end
of ta-VNS, respectively.
Health-related quality of life (QOL): parent’s percep-
tions of the child’s general behavioral problems will be
quantified by using the total score of Achenbach’s Child
Behavior Checklist (CBCL) [13]. The CBCL for ages
1.5–5 years and for ages 6–18 years are 99-item and
118-item questionnaires, respectively, and assesses be-
havioral problems in children. The guardians of the pa-
tients will be asked to rate whether a behavioral problem
is present or not in the child and to what degree.
Side-effects or adverse outcomes: information about
adverse outcomes will be recorded in the diary by the
patient or their guardian. If a possible side-effect or
adverse reaction occurs, the patient or their guardian
should discontinue the stimulation and contact the doc-
tor who will make a judgment. If serious side-effects
occur, the doctor can then unblind the participant and
give the patient post-trial care. All side-effects will be
recorded and reported.
Detailed information about the whole schedule is sum-
marized in Table 1.
Quality control and trial monitoring
Before the initiation of the trial, the researcher will for-
mulate an investigator’s brochure, standard operating
procedures and detailed research plan. All the staff
should participate in special training, including enrolling
patients, completing the case report form and usage of
the stimulator. The data monitoring committee has been
established, which is independent from the sponsor and
competing interests. Monitors will check case report
forms at the participating hospitals once a month. Drop-
outs and withdrawals (and the reasons) from the study
will be fully documented throughout. All the data,
Table 1 Detailed schedule of the protocol
Schedule Baseline Treatment phase Follow-up phase







ta-VNS group Transcutaneous stimulation at the auricular concha
tan-VNS group Transcutaneous stimulation at marginal area of the auricle
Comparison
Control group No transcutaneous stimulation is provided
Outcomes





Adverse events × × × × × ×
The symbol ‘x’ is used as a check mark
EEG electroencephalogram; HRV heart rate variability; QOL quality of life; ta-VNS transcutaneous auricular vagus nerve stimulation; tan-VNS transcutaneous
auricular non-vagus nerve stimulation
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ments, will be kept by special staff. The trial sponsor
(BZ) has access to the final trial dataset.
The final report will follow the Consolidated Standards
of Reporting Trials (CONSORT) extension guideline for
non-pharmaceutical interventions. In order to minimize
6 months’ attrition, first we will enrol patients whose
guardians can understand the mechanism of the ta-VNS
treatment and our previous results. Second, in the con-
sent inform, the participant and their guardian will be
informed that the patient can get doctor consultation
during the whole study period. They can also get a phys-
ical examination (EEG and HRV) and an auricular vagus
nerve stimulator for free when they complete the study.
The doctor will keep in touch with the patients once a
month by phone or email. Additional file 1 describes the
protocol in more detail.
Statistical analysis
The intention-to-treat population will be defined as the
participants who are randomized and received at least
one treatment session. An interim analysis will be per-
formed on the primary endpoint when 50 % of patients
have been randomized and have completed the 1.5 years’
follow-up. The interim analysis will be performed by an
independent statistician, blinded for the treatment allo-
cation. All statistical calculations will be performed usingSPSS v.17.0. Comparison of seizure frequency, HRV and
QOL between baseline and after treatment will be ana-
lyzed by paired-samples t-test. The Kolmogorov-Smirnov
test will be used to evaluate if groups fit normal distribu-
tions. Normally distributed groups will be analyzed by
parametric tests. Comparisons between the three groups
will be analyzed by one-way ANOVA followed by Stu-
dent–Newman–Keuls or Dunnett’s T3 post-hoc tests.
Non-normally distributed groups will be analyzed by
Mann–Whitney’s test. The factors that affect curative
effect will be analyzed with the multinomial logistic
regression method. A P value <0.05 will be considered
of statistical significance.Discussion
Vagus nerve stimulation (VNS) is effective in refractory
epilepsy and depression, and is being investigated in
heart failure, headache, gastric motility disorders and
asthma [4]. In addition to the suppression of seizure fre-
quency, QOL of the pediatric patients with epilepsy also
improved by VNS [14]. In patients with drug-resistant
focal epilepsy, VNS reduces cardiac electrical instability,
potentially by improving autonomic imbalance in favor
of parasympathetic dominance [15]. Nonetheless, ad-
verse events are generally associated with implantation
or continuous on-off stimulation, including infection,
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headache, dyspnea, pharyngitis and pain [4].
As the only peripheral branch of the vagus nerve, the
ABVN has been suggested as a target of transcutaneous
vagus nerve stimulation (t-VNS). In comparison with
VNS, t-VNS is more economic with less side-effects.
Particularly for pediatric patients, transcutaneous stimu-
lation is preferred. In addition to epilepsy, ta-VNS is
now being investigated in anti-atrial fibrillation [16], de-
pression [17] and tinnitus [18]. It has been reported that
in healthy participants, active t-VNS significantly in-
creased HRV and reduced sympathetic nerve outflow
[19]. Yet the relationship between the anticonvulsive
effect of ta-VNS and the improvement of autonomic
imbalance needs to be further investigated.
Although the mechanism of the anticonvulsive effect
of VNS is unclear, it has been suggested to be mediated
via vagal afferent projections to the nucleus tractus soli-
tarius (NTS), then via pathways from the NTS to other
brain structures which correlate with the pathogenesis of
epilepsy [20]. Animal studies have shown an anatomical
relationship between the ABVN and the NTS, and ta-
VNS significantly suppressed epileptiform activity in
EEG traces via increasing the firing rates of the neurons
of the NTS [21]. Studies in humans have shown that
auricular conchae stimulation produced significant acti-
vation of the central vagal projections including wide-
spread activity in the ipsilateral NTS [22]. The NTS
receives and integrates visceral autonomic afferent infor-
mation, which indicates the possibility of the NTS par-
ticipating in the anticonvulsive effect of ta-VNS.
Currently, there are no RCTs investigating ta-VNS for
pediatric patients with epilepsy. Here, we designed this
study to conduct a RCT to examine the potential effect
of ta-VNS and its possible mechanism.
Trial status
This trial is currently recruiting participants. To date (15
February 2015), 35 participants have been recruited.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist. The protocol adheres to
the SPIRIT guidelines. (DOCX 23 kb)
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